MEDIA RELEASE, 30 November 2023, Brisbane Australia: A study conducted by Implicit Bioscience of more than 90 million patient records over ten years from 56 US healthcare organisations has revealed an alarming heart failure incidence of up to 26% in the 12 months following a severe heart attack.
The American Journal of Cardiology this week published the study in which real-world data were analysed to assist the Company with estimating the potential impact of Implicit’s cardioimmunology program.
While rapid-response treatment of heart attack victims has improved their short-term survival rate, longer term consequences, including heart failure, are driven by the body’s immune response that can persist for many months. Implicit’s monoclonal antibody atibuclimab (IC14) has US FDA approval to commence clinical studies in patients with ST-segment elevation myocardial infarction and cardiomyopathy which are planned for early in 2024.
Atibuclimab selectively attenuates the inflammatory response that drives fibrosis, arrhythmias, heart failure and sudden cardiac death.
“In our detailed conversations with a number of international pharmaceutical companies we were surprised to find that there was some uncertainty about just how many patients suffer heart failure following the worst kind of heart attack. That prompted us to conduct the most comprehensive study ever undertaken of the subject in the largest health care market in the world,” said Implicit Bioscience CEO and MD, Garry Redlich.
“We all know that heart disease is the leading disease killer worldwide and accounts for more than a quarter of US deaths, and with nearly a quarter of a million of these serious heart attacks each year. there is still no drug approved to prevent heart failure in up to 60,000 patients who lose the battle in the following 12 months.”
The Company collaborated with Professor Ben van Tassell Pharm. D of the Department of Pharmacotherapy and Outcomes Science at Virginia Commonwealth University and Professor Antonio Abbate MD PhD, a leading cardioimmunologist at the University of Virginia who is working with Implicit on its clinical programs in the US and Europe.
Reference: van Tassell, et al., A Real-World Analysis of New-Onset Heart Failure After Anterior Wall ST-Elevation Acute Myocardial Infarction in the United States of America. The American Journal of Cardiology https://pubmed.ncbi.nlm.nih.gov/37981000/